English | 简体中文 | 繁體中文 | 한국어
Share:
Lubrizol LifeSciences to Showcase New Medical Device Applications Lab at MDM West 2019
Lubrizol LifeSciences to Showcase New Medical Device Applications Lab at MDM West 2019

News Release

Lubrizol LifeSciences to Showcase New Medical
Device Applications Lab at MD&M West 2019

CLEVELAND, February 5, 2019 - The Lubrizol Corporation announces its LifeSciences business will feature a new medical device applications lab. LifeSciences has invested significantly to expand its global development and manufacturing facilities, and the latest investment is a new state-of-the-art medical device applications lab in Brecksville, Ohio. This lab features applications testing, small-scale compounding as well as injection molding for long-term implantables. The 1,800-square foot facility will also focus on accelerated R&D, from polymers to device scale up and testing in a short period of time.

The medical device applications lab is yet another substantial piece of LifeSciences' full-service capabilities. These capabilities and more will be on display at the MD&M West Exposition (Booth #2401), February 5-7. Lubrizol LifeSciences is a preferred medical device development partner, helping customers from concept to commercialization by offering polymer customization, drug-eluting device development and contract manufacturing services. At MD&M, LifeSciences will also highlight a strong presence in the interventional catheter, long-term implant and drug-eluting device markets. In addition, LifeSciences will unveil new dexamethasone-loaded polymers designed to minimize inflammation and help ensure the success of implantable medical devices.

"The new applications lab is another commitment to healthcare companies looking for a full-service development partner. We continue to invest in the right areas to provide valuable offerings where our customers are experiencing the most growth," states Uwe Winzen, general manager, Lubrizol LifeSciences. "When customers partner with Lubrizol LifeSciences, they benefit from working with us at every stage in their development process."

Offering more than 90 years of science and technology experience, Lubrizol is uniquely structured to partner with medical device manufacturers by providing proactive innovation, speed to market, and expertise for the most demanding projects. From materials to development and manufacturing, or anything in between - Lubrizol LifeSciences is equipped to support the needs of customers worldwide.


About Lubrizol LifeSciences
Lubrizol LifeSciences is a preferred Contract Development and Manufacturing Organization (CDMO) partner for complex pharmaceuticals and high-end medical devices providing differentiated polymers and excipients, along with state-of-the-art design, development and manufacturing services to the healthcare industry.

About The Lubrizol Corporation
The Lubrizol Corporation, a Berkshire Hathaway company, is a market-driven global company that combines complex, specialty chemicals to optimize the quality, performance and value of customers' products while reducing their environmental impact. It is a leader at combining market insights with chemistry and application capabilities to deliver valuable solutions to customers in the global transportation, industrial and consumer markets. Lubrizol improves lives by acting as an essential partner in our customers' success, delivering efficiency, reliability or wellness to their end users. Technologies include lubricant additives for engine oils, driveline and other transportation-related fluids, industrial lubricants, as well as additives for gasoline and diesel fuel. In addition, Lubrizol makes ingredients and additives for home care, personal care and skin care products and specialty materials encompassing polymer and coatings technologies, along with polymer-based pharmaceutical and medical device solutions.

With headquarters in Wickliffe, Ohio, Lubrizol owns and operates manufacturing facilities in 17 countries, as well as sales and technical offices around the world. Founded in 1928, Lubrizol has approximately 8,700 employees worldwide. Revenues for 2017 were $6.3 billion. For more information, visit Lubrizol.com.

Media Contact
Ben Patti
(216) 447-5827
[email protected]30T
30Twww.lubrizol.com/LifeSciences30T

###





This announcement is distributed by West Corporation on behalf of West Corporation clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Lubrizol via Globenewswire

Copyright © Thomson Reuters 2019. All rights reserved.
Press Releases
SDLP - Seadrill Partners Announces Contract Award for the West Polaris  
July 19, 2019 12:23 ET
Transparency notification  
July 18, 2019 22:01 ET
XPO Logistics Supports Charitable Bike Build in Northeast Ohio  
July 18, 2019 13:30 ET
Novartis delivers strong sales, double digit core operating income growth and launches Zolgensma and Piqray in second quarter; sales and profit guidance increased  
July 18, 2019 07:00 ET
XPO Logistics Sends 33 Winning Drivers to National Truck Driving Championships  
July 17, 2019 13:30 ET
Eastman Schedules Second-Quarter 2019 Financial Results News Release and SEC Form 8-K Filing, Teleconference and Webcast  
July 8, 2019 22:59 ET
AIR Publishes Its Catastrophe Exposure Data Schema Publicly  
July 1, 2019 16:59 ET
AIR Worldwide Releases Expanded Inland Flood Model for Central Europe  
June 25, 2019 16:29 ET
AIR Worldwide Releases Updated Earthquake Model for New Zealand  
June 20, 2019 16:59 ET
Eastman to Acquire INACSA  
June 19, 2019 20:29 ET
More News >>
Copyright © 2019 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Privacy Policy | Terms of Use | RSS
US: +1 800 291 0906 | Beijing: +86 10 8405 3688 | Hong Kong: +852 2217 2912 | Singapore: +65 6304 8926 | Tokyo: +81 3 5791 1818

Connect With us: